Dextrothyroxine
Choloxin (dextrothyroxine) is a small molecule pharmaceutical. Dextrothyroxine was first approved as Choloxin on 1982-01-01. It is used to treat coronary artery disease, hypercholesterolemia, and hyperlipoproteinemias in the USA. The pharmaceutical is active against thyroid hormone receptor beta and thyroid hormone receptor alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypercholesterolemia | — | D006937 | — |
| coronary artery disease | — | D003324 | I25.1 |
| hyperlipoproteinemias | — | D006951 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | 1 | 2 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | 1 | 2 |
| Coronary disease | D003327 | — | — | — | — | 1 | — | 1 | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | — | 1 | 2 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | 1 | 2 |
| Infarction | D007238 | EFO_0009463 | — | — | — | 1 | — | 1 | 2 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dextrothyroxine |
| INN | dextrothyroxine sodium |
| Description | D-thyroxine is the D-enantiomer of thyroxine. It is a thyroxine and a D-tyrosine derivative. It is an enantiomer of a L-thyroxine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 51-49-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL559 |
| ChEBI ID | 30659 |
| PubChem CID | 8730 |
| DrugBank | DB00509 |
| UNII ID | J60FX7V025 (ChemIDplus, GSRS) |
Target
Agency Approved
THRA
THRA
Organism
Homo sapiens
Gene name
THRA
Gene synonyms
EAR7, ERBA1, NR1A1, THRA1, THRA2
NCBI Gene ID
Protein name
thyroid hormone receptor alpha
Protein synonyms
c-erbA protooncogene, c-erbA-1, c-erbA-alpha, EAR-7, ERBA-related 7, Nuclear receptor subfamily 1 group A member 1, thyroid hormone receptor alpha 1, thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a) oncogene homolog, avian), triiodothyronine receptor, V-erbA-related protein 7
Uniprot ID
Mouse ortholog
Thra (21833)
thyroid hormone receptor alpha (Q99146)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 138 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use